Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.

ABSTRACT:

Background

Despite advances in cancer genomics, radiotherapy is still prescribed on the basis of an empirical one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic-adjusted radiation dose (GARD) model to personalise prescription of radiation dose on the basis of the biological effect of a given physical dose of radiation, calculated using individual tumour genomics. We hypothesise that GARD will reveal interpatient heterogeneity associated with opportunities to improve outcomes compared with physical dose of radiotherapy alone. We aimed to test this hypothesis and investigate the GARD-based radiotherapy dosing paradigm.

Methods

We did a pooled, pan-cancer analysis of 11 previously published clinical cohorts of unique patients with seven diff

SUBMITTER: Scott JG 

PROVIDER: S-EPMC12818176 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature